Israel based real-world study shows that omicron-targeted COVID-19 vaccine from Pfizer IncPFE and BioNTech SEBNTX reduced hospitalizations among older patients.
The study has not yet been peer-reviewed.
Data exhibited an 81% reduction in hospitalizations among people aged 65 and older who had received the booster against those who had previously received at least two COVID vaccinations but not the omicron-adapted shot.
The study was conducted among around 622,700 people who were eligible for the bivalent booster between September to mid-December. Reuters reported that 85,314, or 14%, had received it.
The study said that hospitalization due to Covid-19 occurred in 6 bivalent recipients and 297 participants who did not” receive it. “Death due to Covid-19 occurred in 1 bivalent recipient and 73 participants who did not.”
Though the 86% drop in mortality was statistically borderline because of the relatively low death rates in the country, it was nonetheless significant, the researchers said.
Price Action: PFE shares are down 2.77% at $49.51, and BNTX shares are up 0.67% at $151.09 on the last check Monday.
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
